# A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SR1375

> **NCT05026008** · PHASE1 · COMPLETED · sponsor: **Shanghai SIMR Biotechnology Co., Ltd.** · enrollment: 72 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** SR1375
- **DRUG:** Matching placebo

## Key facts

- **NCT ID:** NCT05026008
- **Lead sponsor:** Shanghai SIMR Biotechnology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-30
- **Primary completion:** 2022-11-30
- **Final completion:** 2023-03-30
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2024-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05026008

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05026008, "A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SR1375". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05026008. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*